JUVE Patent

Danish packaging manufacturer Hartmann Packaging and its German competitor Omni-pac have been in dispute over EP 2 755 901 at the Unified Patent Court for more than two years. In March 2024, Hartmann brought an infringement action against two Omni-pac ent

The guidelines, dated 13 August 2026, summarise the reasoning behind four major recent SEP decisions handed down earlier this year by the 7th Civil Chamber: ASUS I, ASUS II, Renault and ZTE v Samsung. The parallel 21st Civil Chamber has been informed of t

Arbutus and Genevant Sciences, are no strangers to the Unified Patent Court. Last year, the two companies filed two claims against Moderna at the The Hague local division as part of a global litigation campaign. However, the dispute did not last long. In

The parties are fighting over EP 1 467 728. The patent protects the combination of the angiotensin receptor blocker valsartan and the neutral endopeptidase inhibitor sacubitril. The two compounds form the basis of Novartis' drug Entresto, used globally to

Edwards began his career as a trainee solicitor at Linklaters in 2000, before joining Bird & Bird as a solicitor in 2002. In 2007, he moved to Australian firm Freehills as a senior associate, having previously spent time at Mallesons Stephen Jaques. In 20

Atlas Global Technologies, a US-based non-practising entity, owns the two patents EP 3 353 901 and EP 3 186 937. The patents relate to wireless communication technology in the wifi standard. The patent holder sued Singapore based TP-Link and French Vantiv

The rulings mark the latest chapter in a long-running dispute in which US patent holder WobbleWorks is defending its 3Doodler technology against various Asian competitors. The current dispute revolves around WobbleWorks' EP 3 698 938 B1, which protects a

Japanese consumer electronics company Maxell had sued four Samsung entities before the UPC's local division The Hague, alleging that various Galaxy smartphones and tablets infringed device claims of EP 2 061 230. The patent, granted in 2011 and validated

Novo Nordisk continues its efforts to defend the market exclusivity of its blockbuster semaglutide products in Europe. In a judgment handed down yesterday, the District Court The Hague granted the Danish pharmaceutical company a preliminary injunction aga

Continuing its growth strategy, HGF adds life science partner Russell Thom from Murgitroyd to its IP practice in Glasgow.